Cancer Related microRNAs

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".

Deadline for manuscript submissions: closed (31 October 2019) | Viewed by 42146

Special Issue Editor

Special Issue Information

Dear Colleagues,

Among the diseases for which microRNAs are known to play critical roles, cancers have been well studied.

There are many known onco-microRNAs and miRNAs suppressing cancers. In spite of that, how individual miRNAs contribute to the progression or suppression of cancers is unclear. Some miRNAs work as onco-miRNA for specific cancers, but as tumor suppressors for others. Further, the expression of onco-miRNA can be suppressed on metastasis.

We invite authors to submit studies related to the identification of novel onco-miRNAs and tumor suppressor microRNAs as well as their mechanisms to this Special Issue of Cells “Cancer-Related microRNA”.

Prof. Y-h. Taguchi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • renal cancer
  • breast cancer
  • pancreatic cancer
  • lung cancer
  • non-small cell lung cancer
  • colon cancer
  • brain tumor
  • leukemia
  • epigenetic therapy

Published Papers (8 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2451 KiB  
Article
miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia
by Valentina Saccomani, Angela Grassi, Erich Piovan, Deborah Bongiovanni, Ludovica Di Martino, Sonia Minuzzo, Valeria Tosello and Paola Zanovello
Cells 2020, 9(7), 1726; https://0-doi-org.brum.beds.ac.uk/10.3390/cells9071726 - 18 Jul 2020
Cited by 17 | Viewed by 3129
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive disease arising from T-cell precursors. NOTCH1 plays an important role both in T-cell development and leukemia progression, and more than 60% of human T-ALLs harbor mutations in components of the NOTCH1 signaling pathway, leading [...] Read more.
T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive disease arising from T-cell precursors. NOTCH1 plays an important role both in T-cell development and leukemia progression, and more than 60% of human T-ALLs harbor mutations in components of the NOTCH1 signaling pathway, leading to deregulated cell growth and contributing to cell transformation. Besides multiple NOTCH1 target genes, microRNAs have also been shown to regulate T-ALL initiation and progression. Using an established mouse model of T-ALL induced by NOTCH1 activation, we identified several microRNAs downstream of NOTCH1 activation. In particular, we found that NOTCH1 inhibition can induce miR-22-3p in NOTCH1-dependent tumors and that this regulation is also conserved in human samples. Importantly, miR-22-3p overexpression in T-ALL cells can inhibit colony formation in vitro and leukemia progression in vivo. In addition, miR-22-3p was found to be downregulated in T-ALL specimens, both T-ALL cell lines and primary samples, relative to immature T-cells. Our results suggest that miR-22-3p is a functionally relevant microRNA in T-ALL whose modulation can be exploited for therapeutic purposes to inhibit T-ALL progression. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Figure 1

16 pages, 3218 KiB  
Article
Let-7 miRNA’s Expression Profile and Its Potential Prognostic Role in Uterine Leiomyosarcoma
by Bruna Cristine de Almeida, Laura Gonzalez dos Anjos, Miyuki Uno, Isabela Werneck da Cunha, Fernando Augusto Soares, Glauco Baiocchi, Edmund Chada Baracat and Katia Candido Carvalho
Cells 2019, 8(11), 1452; https://0-doi-org.brum.beds.ac.uk/10.3390/cells8111452 - 17 Nov 2019
Cited by 16 | Viewed by 2979
Abstract
The lethal-7 (let-7) family is an important microRNA (miRNA) group that usually exerts functions as a tumor suppressor. We aimed to evaluate the expression profile of let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, and let-7i and to assess their value as prognostic [...] Read more.
The lethal-7 (let-7) family is an important microRNA (miRNA) group that usually exerts functions as a tumor suppressor. We aimed to evaluate the expression profile of let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, and let-7i and to assess their value as prognostic markers in uterine leiomyosarcoma (LMS) patients. The miRNAs expression profile was assessed in 34 LMS and 13 normal myometrium (MM) paraffin-embedded samples. All let-7 family members showed downregulation in LMS. Our findings showed that patients with let-7e downregulation had worse overall survival (OS) and is an independent prognostic factor (hazard ratio [HR] = 2.24). In addition, almost half the patients had distant metastasis. LMS patients with downregulated let-7b and let-7d had worse disease-free survival (DFS); they are not independent prognostic factors (HR = 2.65). Patients’ ages were associated with let-7d, let-7e and let-7f (p = 0.0160) downregulation. In conclusion, all the let-7 family members were downregulated in LMS patients, and the greater the loss of expression of these molecules, the greater their relationship with worse prognosis of patients. Let-7e expression might influence the OS, while let-7b and le-7d might influence the DFS. The lowest expression levels of let-7d, let-7e, and let-7f were associated with the oldest patients. Our findings indicate strong evidence of let-7’s role as a potential prognostic biomarker in LMS. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Figure 1

Review

Jump to: Research

37 pages, 2113 KiB  
Review
microRNA: The Impact on Cancer Stemness and Therapeutic Resistance
by Xueqiao Jiao, Xianling Qian, Longyuan Wu, Bo Li, Yi Wang, Xinyu Kong and Lixia Xiong
Cells 2020, 9(1), 8; https://0-doi-org.brum.beds.ac.uk/10.3390/cells9010008 - 18 Dec 2019
Cited by 35 | Viewed by 5456
Abstract
Cancer ranks as the second leading cause of death worldwide, causing a large social and economic burden. However, most anti-cancer treatments face the problems of tumor recurrence and metastasis. Therefore, finding an effective cure for cancer needs to be solved urgently. Recently, the [...] Read more.
Cancer ranks as the second leading cause of death worldwide, causing a large social and economic burden. However, most anti-cancer treatments face the problems of tumor recurrence and metastasis. Therefore, finding an effective cure for cancer needs to be solved urgently. Recently, the discovery of cancer stem cells (CSCs) provides a new orientation for cancer research and therapy. CSCs share main characteristics with stem cells and are able to generate an entire tumor. Besides, CSCs usually escape from current anti-cancer therapies, which is partly responsible for tumor recurrence and poor prognosis. microRNAs (miRNAs) belong to small noncoding RNA and regulate gene post-transcriptional expression. The dysregulation of miRNAs leads to plenty of diseases, including cancer. The aberrant miRNA expression in CSCs enhances stemness maintenance. In this review, we summarize the role of miRNAs on CSCs in the eight most common cancers, hoping to bridge the research of miRNAs and CSCs with clinical applications. We found that miRNAs can act as tumor promoter or suppressor. The dysregulation of miRNAs enhances cell stemness and contributes to tumor metastasis and therapeutic resistance via the formation of feedback loops and constitutive activation of carcinogenic signaling pathways. More importantly, some miRNAs may be potential targets for diagnosis, prognosis, and cancer treatments. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Figure 1

20 pages, 876 KiB  
Review
Cell-Free microRNAs as Potential Oral Cancer Biomarkers: From Diagnosis to Therapy
by Óscar Rapado-González, Rafael López-López, José Luis López-Cedrún, Gabriel Triana-Martínez, Laura Muinelo-Romay and María Mercedes Suárez-Cunqueiro
Cells 2019, 8(12), 1653; https://0-doi-org.brum.beds.ac.uk/10.3390/cells8121653 - 17 Dec 2019
Cited by 29 | Viewed by 5126
Abstract
Oral cavity cancer is the most frequent malignancy of the head and neck. Unfortunately, despite educational interventions for prevention and early diagnosis, oral cancer patients are often diagnosed in advanced stages associated with poor prognosis and life expectancy. Therefore, there is an urgent [...] Read more.
Oral cavity cancer is the most frequent malignancy of the head and neck. Unfortunately, despite educational interventions for prevention and early diagnosis, oral cancer patients are often diagnosed in advanced stages associated with poor prognosis and life expectancy. Therefore, there is an urgent need to find noninvasive biomarkers to improve early detection of this tumor. Liquid biopsy has emerged as a valuable tool in medical oncology which provides new horizons for improving clinical decision making. Notably, cell-free microRNAs (miRNAs), a class of short non-coding RNAs, are emerging as novel noninvasive cancer biomarkers. Here, we provide an overview of the potential clinical application of cell-free miRNAs as diagnostic, prognostic, and therapeutic biomarkers in oral cancer. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Figure 1

22 pages, 2362 KiB  
Review
The Butterfly Effect of RNA Alterations on Transcriptomic Equilibrium
by Ng Desi and Yvonne Tay
Cells 2019, 8(12), 1634; https://0-doi-org.brum.beds.ac.uk/10.3390/cells8121634 - 13 Dec 2019
Cited by 8 | Viewed by 4534
Abstract
Post-transcriptional regulation plays a key role in modulating gene expression, and the perturbation of transcriptomic equilibrium has been shown to drive the development of multiple diseases including cancer. Recent studies have revealed the existence of multiple post-transcriptional processes that coordinatively regulate the expression [...] Read more.
Post-transcriptional regulation plays a key role in modulating gene expression, and the perturbation of transcriptomic equilibrium has been shown to drive the development of multiple diseases including cancer. Recent studies have revealed the existence of multiple post-transcriptional processes that coordinatively regulate the expression and function of each RNA transcript. In this review, we summarize the latest research describing various mechanisms by which small alterations in RNA processing or function can potentially reshape the transcriptomic landscape, and the impact that this may have on cancer development. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Figure 1

36 pages, 2605 KiB  
Review
MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer
by Lei Ding, Huan Gu, Xianhui Xiong, Hongshun Ao, Jiaqi Cao, Wen Lin, Min Yu, Jie Lin and Qinghua Cui
Cells 2019, 8(12), 1492; https://0-doi-org.brum.beds.ac.uk/10.3390/cells8121492 - 22 Nov 2019
Cited by 109 | Viewed by 6338
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive, prevalent, and distinct subtype of breast cancer characterized by high recurrence rates and poor clinical prognosis, devoid of both predictive markers and potential therapeutic targets. MicroRNAs (miRNA/miR) are a family of small, endogenous, non-coding, single-stranded [...] Read more.
Triple-negative breast cancer (TNBC) is the most aggressive, prevalent, and distinct subtype of breast cancer characterized by high recurrence rates and poor clinical prognosis, devoid of both predictive markers and potential therapeutic targets. MicroRNAs (miRNA/miR) are a family of small, endogenous, non-coding, single-stranded regulatory RNAs that bind to the 3′-untranslated region (3′-UTR) complementary sequences and downregulate the translation of target mRNAs as post-transcriptional regulators. Dysregulation miRNAs are involved in broad spectrum cellular processes of TNBC, exerting their function as oncogenes or tumor suppressors depending on their cellular target involved in tumor initiation, promotion, malignant conversion, and metastasis. In this review, we emphasize on masses of miRNAs that act as oncogenes or tumor suppressors involved in epithelial–mesenchymal transition (EMT), maintenance of stemness, tumor invasion and metastasis, cell proliferation, and apoptosis. We also discuss miRNAs as the targets or as the regulators of dysregulation epigenetic modulation in the carcinogenesis process of TNBC. Furthermore, we show that miRNAs used as potential classification, prognostic, chemotherapy and radiotherapy resistance markers in TNBC. Finally, we present the perspective on miRNA therapeutics with mimics or antagonists, and focus on the challenges of miRNA therapy. This study offers an insight into the role of miRNA in pathology progression of TNBC. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Graphical abstract

38 pages, 2989 KiB  
Review
MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer
by Mohammad Mijanur Rahman, Andrew C. Brane and Trygve O. Tollefsbol
Cells 2019, 8(10), 1214; https://0-doi-org.brum.beds.ac.uk/10.3390/cells8101214 - 08 Oct 2019
Cited by 79 | Viewed by 8534
Abstract
Breast cancer is a sporadic disease with genetic and epigenetic components. Genomic instability in breast cancer leads to mutations, copy number variations, and genetic rearrangements, while epigenetic remodeling involves alteration by DNA methylation, histone modification and microRNAs (miRNAs) of gene expression profiles. The [...] Read more.
Breast cancer is a sporadic disease with genetic and epigenetic components. Genomic instability in breast cancer leads to mutations, copy number variations, and genetic rearrangements, while epigenetic remodeling involves alteration by DNA methylation, histone modification and microRNAs (miRNAs) of gene expression profiles. The accrued scientific findings strongly suggest epigenetic dysregulation in breast cancer pathogenesis though genomic instability is central to breast cancer hallmarks. Being reversible and plastic, epigenetic processes appear more amenable toward therapeutic intervention than the more unidirectional genetic alterations. In this review, we discuss the epigenetic reprogramming associated with breast cancer such as shuffling of DNA methylation, histone acetylation, histone methylation, and miRNAs expression profiles. As part of this, we illustrate how epigenetic instability orchestrates the attainment of cancer hallmarks which stimulate the neoplastic transformation-tumorigenesis-malignancy cascades. As reversibility of epigenetic controls is a promising feature to optimize for devising novel therapeutic approaches, we also focus on the strategies for restoring the epistate that favor improved disease outcome and therapeutic intervention. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Figure 1

20 pages, 1668 KiB  
Review
The Role of miRNAs in Immune Cell Development, Immune Cell Activation, and Tumor Immunity: With a Focus on Macrophages and Natural Killer Cells
by Shi Jun Xu, Hong Tao Hu, Hai Liang Li and Suhwan Chang
Cells 2019, 8(10), 1140; https://0-doi-org.brum.beds.ac.uk/10.3390/cells8101140 - 24 Sep 2019
Cited by 48 | Viewed by 5408
Abstract
The tumor microenvironment (TME) is the primary arena where tumor cells and the host immune system interact. Bidirectional communication between tumor cells and the associated stromal cell types within the TME influences disease initiation and progression, as well as tumor immunity. Macrophages and [...] Read more.
The tumor microenvironment (TME) is the primary arena where tumor cells and the host immune system interact. Bidirectional communication between tumor cells and the associated stromal cell types within the TME influences disease initiation and progression, as well as tumor immunity. Macrophages and natural killer (NK) cells are crucial components of the stromal compartment and display either pro- or anti-tumor properties, depending on the expression of key regulators. MicroRNAs (miRNAs) are emerging as such regulators. They affect several immune cell functions closely related to tumor evasion of the immune system. This review discusses the role of miRNAs in the differentiation, maturation, and activation of immune cells as well as tumor immunity, focusing particularly on macrophages and NK cells. Full article
(This article belongs to the Special Issue Cancer Related microRNAs)
Show Figures

Figure 1

Back to TopTop